Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBU-TAB 200 vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Pain,Fever,Inflammation,Dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Migraine
Osteoarthritis,Rheumatoid arthritis
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
600 mg orally once daily; max 1200 mg/day
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Hepatic metabolism primarily via CYP2C9.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
99% bound to albumin.
>99% bound primarily to albumin.
0.1-0.2 L/kg (low Vd, confined to plasma and interstitial fluid).
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: 80-100% (with food may reduce rate).
Oral: approximately 80-90%.
e GFR 30-59 m L/min: reduce dose by 50% or increase interval to every 8-12 hours; e GFR <30 m L/min: avoid use or maximum 400 mg/day.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. For fever or pain: 5 mg/kg per dose for temperatures <102.5°F, 10 mg/kg per dose for higher fever.
Not approved for pediatric use
Start at lowest effective dose (200 mg every 6-8 hours); maximum 400 mg/day due to increased risk of renal and GI adverse effects.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, hepatic effects, asthma exacerbation, pregnancy avoidance (third trimester).
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Hypersensitivity to ibuprofen or NSAIDs, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of coronary artery bypass graft (CABG) surgery, severe renal impairment, active peptic ulcer disease.
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Avoid alcohol. Take with food or milk to minimize gastric irritation. Grapefruit juice may modestly increase ibuprofen absorption but clinical significance is low; no strict restriction. Administer with a full glass of water.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; no clear teratogenic risk but may cause premature closure of ductus arteriosus. Third trimester: Contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. Monitor infant for rash, gastrointestinal effects, or drowsiness.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
No specific dose adjustment recommended for pregnancy-related pharmacokinetic changes. However, due to increased plasma volume and renal clearance, therapeutic efficacy may be reduced; use lowest effective dose. Avoid in third trimester.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
Ibuprofen (IBU-TAB 200) is an NSAID; avoid in patients with Cr Cl <30 m L/min. Dose adjustment not needed for mild hepatic impairment but contraindicated in severe hepatic disease. Use lowest effective dose for shortest duration to minimize renal and GI risk. Can mask signs of infection; monitor for fever in at-risk patients. Not recommended in late pregnancy (after 30 weeks) due to risk of premature ductus arteriosus closure.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
Take with food or milk to reduce gastrointestinal upset.,Do not exceed 1200 mg per day without consulting your doctor.,Avoid drinking alcohol while taking this medication as it increases the risk of stomach bleeding.,If you have high blood pressure, heart disease, or kidney disease, use only under medical supervision.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of allergic reaction (rash, swelling, difficulty breathing).,Do not take with other NSAIDs (e.g., aspirin, naproxen) unless directed by your doctor.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBU-TAB 200 vs DAYPRO, answered by our medical review team.
IBU-TAB 200 is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBU-TAB 200 and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBU-TAB 200 is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBU-TAB 200 and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBU-TAB 200 is classified as Category C. First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; n. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.